• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

Research Brief on (2R)-2-(2,3-Dihydro-1H-inden-1-yl)propan-1-amine (CAS: 2248219-14-7): Recent Advances and Applications

The compound (2R)-2-(2,3-Dihydro-1H-inden-1-yl)propan-1-amine (CAS: 2248219-14-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This chiral amine derivative, characterized by its indane scaffold, has shown promising potential in various therapeutic applications, particularly in the modulation of central nervous system (CNS) targets. Recent studies have focused on its synthesis, pharmacological properties, and potential as a lead compound for drug development.

A 2023 study published in the Journal of Medicinal Chemistry explored the enantioselective synthesis of (2R)-2-(2,3-Dihydro-1H-inden-1-yl)propan-1-amine, highlighting its high purity and yield through asymmetric hydrogenation. The research emphasized the compound's structural versatility, which allows for further derivatization to enhance its pharmacological profile. The study also reported its binding affinity to serotonin and dopamine receptors, suggesting potential applications in neuropsychiatric disorders such as depression and Parkinson's disease.

In another recent investigation, researchers evaluated the compound's pharmacokinetic properties, including its metabolic stability and blood-brain barrier permeability. The results, published in Drug Metabolism and Disposition, indicated favorable oral bioavailability and CNS penetration, making it a viable candidate for further preclinical development. Additionally, in vitro assays demonstrated its low cytotoxicity, further supporting its therapeutic potential.

Emerging applications of (2R)-2-(2,3-Dihydro-1H-inden-1-yl)propan-1-amine extend beyond CNS disorders. A 2024 study in ACS Chemical Biology revealed its role as a scaffold for designing novel enzyme inhibitors, particularly targeting kinases involved in inflammatory pathways. This finding opens new avenues for treating autoimmune diseases and chronic inflammation.

In conclusion, (2R)-2-(2,3-Dihydro-1H-inden-1-yl)propan-1-amine (CAS: 2248219-14-7) represents a multifaceted compound with broad therapeutic potential. Ongoing research aims to optimize its derivatives for enhanced efficacy and selectivity, positioning it as a promising candidate for future drug discovery efforts. Further studies are warranted to explore its full mechanistic profile and clinical applicability.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)